Mezzion Pharma Co.,Ltd. (KOSDAQ: 140410)

Market Cap	924.37B
Revenue (ttm)	14.08B
Net Income (ttm)	-14.22B
Shares Out	29.96M
EPS (ttm)	-478.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,778
Average Volume	74,959
Open	30,900
Previous Close	30,650
Day's Range	30,750 - 31,550
52-Week Range	27,000 - 50,200
Beta	0.56
RSI	49.98
Earnings Date	Mar 21, 2025

About Mezzion Pharma Co.,Ltd.

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 17
• Stock Exchange: KOSDAQ
• Ticker Symbol: 140410

Financial Performance

In 2023, Mezzion Pharma Co.,Ltd.'s revenue was 31.72 billion, an increase of 3.24% compared to the previous year's 30.73 billion. Losses were -12.73 billion, -64.93% less than in 2022.